Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/166560
Diabetic Retinopathy and Ocular Melanoma: How far we are?
Journal Title
Director/Tutor
Additional contribution
Journal ISSN
Volume Title
Abstract
Diabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment
Related resource
Subject (English)
Citation
Citation
SOUTO, Eliana B., et al. Diabetic Retinopathy and Ocular Melanoma: How far we are?. Applied Sciences. 2020. Vol. 10, num. 2777-. ISSN 2076-3417. [consulted: 9 of October of 2026]. Available at: https://hdl.handle.net/2445/166560